Crucell linked with new takeover suitors
January 29, 2009Sales and Marketing Crucell, MA
Dutch vaccines firm Crucell could be snapped up by other pharmaceutical companies after Wyeth pulled out of negotiations to buy …
Independent study into NICE’s methods
January 29, 2009Sales and Marketing NICE, hc
NICE has asked an eminent academic and NHS reformer to conduct an independent study of its approach to appraising new …
RoActemra approved in Europe
January 29, 2009Sales and Marketing RoActemra, Roche
The European Commission has approved Roche's RoActemra as a treatment for rheumatoid arthritis. Schering-Plough's Remicade, Wyeth's Enbrel and Abbott's Humira …
Plavix sales help BMS into profit
January 29, 2009Sales and Marketing BMS, Plavix
Strong fourth quarter sales of its blockbuster blood thinner Plavix have helped Bristol-Myers Squibb back into the black. Net earnings …
Novartis launches Extavia in Europe
January 28, 2009Sales and Marketing Extavia, MS
Novartis has launched its new multiple sclerosis injection Extavia in Europe and hopes this will lay the groundwork for an …
Who owns the brand?
January 27, 2009Sales and Marketing branding, marketing
For all of us in brand marketing, it is worth remembering that creating and nurturing a brand can be like …
Roche and Novo Nordisk to restrict distribution
January 27, 2009Manufacturing and Production supply chain
Roche and Novo Nordisk are the latest companies to cut the number of wholesalers allowed to supply their medicines to …
Pfizer unveils $68 billion takeover of Wyeth
January 26, 2009Sales and Marketing MA, Pfizer
Pfizer has unveiled a deal to acquire Wyeth for $68 billion, creating a new giant in pharmaceuticals, biotech, vaccines, consumer …
Green light for kidney cancer drugs in Wales
January 26, 2009Sales and Marketing NHS, par, rcc
Kidney cancer patients in Wales are to gain access to the four new drugs that are still denied on the …
Pfizer to make merger bid for Wyeth
January 26, 2009Sales and Marketing MA, Pfizer
Pfizer looks set to make a multi-billion dollar takeover of fellow US pharma company Wyeth.The world's largest pharma company, Pfizer …
GSK hopeful of NICE approval for Tyverb
January 26, 2009Sales and Marketing Cancer, GSK, breast cancer
NICE could be poised to reverse its rejection of GSK's breast cancer treatment Tyverb, the pharma company has said.NICE rejected …
Working Life: Sam Knivett
January 23, 2009Business Services, Research and Development Pfizer, UK, WL, Working Life, careers, compliance, drug safety
How did you find your way into your current role?From the age of 11 I wanted to be a farmer. …
Merck Serono’s multiple sclerosis drug on track for filing
January 23, 2009Research and Development, Sales and Marketing MS, Merck Serono
Cladribine, a new oral treatment for multiple sclerosis is on track for a mid-2009 filing after the release of encouraging …
Prescription charges abolished for cancer patients
January 23, 2009Sales and Marketing NHS, hc
Cancer patients in England can now apply for free NHS prescriptions, potentially saving individuals up to £100 each year. The …
FDA finalises transgenic animals guide
January 23, 2009Research and Development, Sales and Marketing FDA, US, reg
The route map for companies wishing to sell medicines made in genetically-engineered animals has been drawn up by the FDA. …
Personal health budgets on the horizon
January 22, 2009Sales and Marketing NHS, hc
Patients will have greater choice and more control over the kind of healthcare they receive under new government measures. The …
ReNeuron’s ground-breaking stem cell trial approved
January 22, 2009Research and Development ReNeuron, stem cell
UK biotech ReNeuron has been given the go-ahead for a ground-breaking stem cell clinical trial.The phase I trial of its …
Engaging with the NHS in 2009
January 22, 2009Sales and Marketing NHS, event, healthcare, priorities
Delegates arriving at the conference to the strains of Jeff Wayne's War of the Worlds must have wondered whether they …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
